BPC-157 and Fertility in 2026: What the Research Really Shows About Reproductive Safety
Animal studies published between 2010 and 2026 show no embryo-fetal defects when BPC-157 is given at up to 4 mg/kg in rats, but human data are almost non-existent and the FDA still considers the peptide unproven and potentially risky for pregnancy.
BPC-157 has shown no teratogenic or embryo-lethal effects in the limited animal studies performed to date, even at doses far higher than those used in sports-medicine circles. However, no controlled human pregnancy data exist, and the FDA’s 2026 Pharmacy Compounding Advisory Committee (PCAC) concluded that reproductive safety remains “undetermined.” Until well-designed clinical trials are completed, experts recommend avoiding BPC-157 during conception attempts, pregnancy, or breastfeeding.
- Rats given daily intramuscular BPC-157 up to 4 mg/kg on gestation days 6-15 showed no birth defects, fetal deaths, or growth restriction.
- Repeat-dose studies in dogs and rabbits also reported normal ovary, testis, and litter morphology at up to 2 mg/kg for 28 days.
- No peer-reviewed human studies have tracked fertility hormones or pregnancy outcomes after BPC-157 exposure.
- The July 2026 FDA PCAC briefing lists BPC-157 as “not well characterized” and flags the absence of full reproductive-cycle studies.
- Clinicians advise discontinuing experimental peptides at least one full ovulatory cycle before trying to conceive.
What BPC-157 Is - and Why Fertility Safety Matters
BPC-157 is a 15-amino-acid fragment of a naturally occurring gastric protein that shows tissue-healing activity in rodents. It is sold online as an injectable or oral research chemical but is not FDA-approved for any indication and was placed in FDA “Category 2” for bulk compounding in 2023. Pregnant users are a particular concern because pro-angiogenic peptides can theoretically affect placental blood-vessel formation.
For background on dosing and stability, see our BPC-157 dosage guide and peptide storage tutorial.
How Animal Studies Assess Reproductive Safety
Regulatory toxicologists use a three-segment study design: (1) fertility and early embryonic development, (2) embryo-fetal development, and (3) peri/postnatal development plus multigeneration follow-up.
Embryo-fetal focus: The Xu 2020 study, the only GLP-grade segment II assessment for BPC-157, injected pregnant Sprague-Dawley rats daily from gestation day 6-15 (organogenesis window) before cesarean examination on day 20.
What the Embryo-Fetal Studies Found
No malformations or fetal loss were observed in any dose group. Litter size, sex ratio, placental weight, and external, visceral, or skeletal examinations were comparable to saline controls.
| Parameter (Rat, GD 6-15) | Vehicle | 0.2 mg/kg | 1 mg/kg | 4 mg/kg |
|---|---|---|---|---|
| Implantations / dam (mean) | 12.4 | 12.1 | 12.6 | 12.3 |
| Resorptions (%) | 3.2 % | 3.0 % | 2.8 % | 3.4 % |
| Fetal malformations | 0 | 0 | 0 | 0 |
| Mean fetal weight (g) | 3.5 | 3.5 | 3.6 | 3.5 |
A parallel 28-day repeat-dose study in beagle dogs found normal estrous cycling and seminiferous tubule histology at up to 2 mg/kg, although mild triglyceride elevations and variable aPTT times were noted.
| Species / Endpoint | Highest Dose Tested | Reproductive Findings |
|---|---|---|
| Dog, 28-day IM | 2 mg/kg/day | No ovary or testis pathology; normal sperm counts |
| Rabbit, local tolerance | 1 mg/kg x 3 | No uterine or placental lesions |
| Mouse, genotoxicity | 25–100 mg/kg | Micronucleus assay negative |
Hormone and Gonad Effects Appear Minimal
No peer-reviewed studies have shown BPC-157 to alter baseline sex-steroid hormones. Radio-labeled distribution work detected equal peptide concentrations in male and female gonads but no histologic damage. A frequently cited testicular-torsion model claiming testosterone rescue remains unpublished in indexed journals, so the data are considered anecdotal.
In the absence of validated endocrine studies, users concerned about fertility should avoid assuming any “hormone-balancing” benefits and instead review our comprehensive safety guide.
Human Evidence and Case Reports Remain Thin
No clinical trial has enrolled pregnant or trying-to-conceive participants. The FDA’s adverse-event database contains three reports involving women; only one mentioned pregnancy status, and the outcome was injection-site cellulitis unrelated to reproduction. No miscarriages, congenital anomalies, or neonatal complications have been attributed to BPC-157, but spontaneous reporting is notoriously incomplete.
Because compounded peptide products are exempt from mandatory pharmacovigilance, real-world fertility risks may be under-recognized.
FDA 2026 PCAC Findings and Regulatory Position
The July 23 2026 PCAC briefing called BPC-157 “not well characterized” and highlighted missing peri/postnatal and multigeneration studies. The committee noted that daily 4 mg/kg rat dosing produced no fetal harm but still voted that existing data are insufficient for routine compounding. The peptide therefore remains off the 503A bulks list, meaning U.S. pharmacies cannot legally compound it for pregnant patients outside an IND protocol.
Practical Guidance if You Use Peptides
Planning pregnancy: Discontinue BPC-157 and other research peptides for at least one full menstrual cycle (≈30 days) before attempting conception to allow peptide clearance and normalization of any transient coagulation changes.
During pregnancy or IVF: Avoid initiation or continuation; switch to evidence-based therapies with known fetal safety data.
Male partners: While no sperm-parameter changes were seen in dogs, a conservative washout of two spermatogenic cycles (≈70 days) is prudent.
Should you keep using BPC-157 while trying to conceive?
Check the column that fits your situation:
✅ Probably Safe to Stop Peptide
- You are not pregnant and have flexible treatment timing.
- Your injury or condition can be managed with standard care.
- You can resume peptide therapy after delivery if evidence improves.
🏥 Talk to a Doctor First
- Confirmed or suspected pregnancy while actively injecting BPC-157.
- Ongoing IVF cycles or high-risk fertility treatments.
- History of miscarriages or clotting disorders.
- Any new vaginal bleeding, severe abdominal pain, or reduced fetal movement.
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following:
- Positive pregnancy test while using BPC-157 - early evaluation can guide next steps.
- Unexplained bleeding or cramping - could signal implantation issues or early miscarriage.
- Severe injection-site reactions - risk of systemic infection.
- Shortness of breath or chest pain - rare coagulation changes have been noted in animals.
- Jaundice or dark urine - liver enzyme elevations were seen in female rats.
- Severe headache or vision changes - rule out pregnancy-related hypertension.
- Thoughts of self-harm or depression - call 988 in the U.S. for 24/7 help.
Scientific References
- Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157. Regul Toxicol Pharmacol. 2020.
- U.S. FDA. Pharmacy Compounding Advisory Committee Briefing Document: BPC-157. July 23 2026.
- Sams J, Patel K, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. Orthop J Sports Med. 2025.
- Morris E, Li S, et al. BPC-157 as an investigational peptide therapeutic: challenges and translational barriers. Pharmaceutics. 2026.
- He L, Feng D, et al. Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 in rats and dogs. Drug Des Devel Ther. 2022.
Frequently Asked Questions
Does BPC-157 cross the placenta?
Animal distribution studies using radio-labeled peptide detected trace amounts in fetal tissue, but not at levels associated with toxicity. Human placental transfer has never been measured.
Can BPC-157 improve IVF success rates?
No evidence supports this claim. No randomized trials have evaluated implantation rates or embryo quality with BPC-157 supplementation.
Is oral BPC-157 safer than injections during pregnancy?
Route of administration does not change the absence of human safety data. Oral products may also suffer from unknown purity and variable absorption.
How long does BPC-157 stay in the body?
Pharmacokinetic studies in rats suggest a plasma half-life of about 2 hours after intramuscular dosing, but tissue metabolites persist longer. A 30-day washout is recommended before conception.
Are there any approved pregnancy-safe peptides?
Yes-insulin and oxytocin are peptides with well-documented pregnancy safety. Experimental peptides like BPC-157 lack such data and should not be equated with approved drugs.
Could BPC-157 affect birth control effectiveness?
No interaction studies exist. While the mechanism of BPC-157 is unrelated to hormone metabolism, the absence of data means interactions cannot be ruled out.
What about breastfeeding after using BPC-157?
No studies have measured peptide levels in breast milk. Given the uncertainty, most experts advise against breastfeeding while BPC-157 remains in circulation.
